The founders envisioned having a team of individuals committed to develop innovative ideas in ACT diagnosis and treatment

The ICPACT founders agree to participate in collaborative research efforts including the development and validation of methods and projects

The Founders: Ana Paula Percicote, Bonald Cavalcante de Figueiredo, Camila M. Daiggi, Carmem M. C. M. Fiori, Caroline Brunetto, Eliana N. N. Caran, Emília Modolo Pinto, Enzo Lalli, Gabriela Caus Fernandes Luiz Canali, Gerard P. Zambetti, Humberto Cereser Ibañez, José Alexandre Marzagão Barbuto, Karla Emilia de Sá Rodrigues, Lauro Mera Souza, Mara Albonei Dudeque Pianovski, Maria José Mastellaro, Pablo Santiago, Patricia Brandalise, Raul Correa Ribeiro, Simoni Abib, Silvia Brandalise, Tatiana El Jaick B. Costa, Verena Wiegering and Vilani Kremer.

Our mission

“To construct the future with the lowest mortality rates for pediatric adrenocortical carcinoma”

Coordinator

• Scientific Director of the Pelé Pequeno Príncipe Research Institute, Curitiba, PR, Brazil
• Coordinator of the PhD Program in Biotechnology Applied to the Health of the Chield and the Adolescent, Faculdades Pequeno Príncipe
• Pequeno Príncipe Biobank Director

 From May, 2023 to November, 2024: Bonald C. Figueiredo, MD, PhD

The next volunteer to become coordinator (Camila Daiggi) will be in charge of organizing the ICPACT International Workshop in her institution (Boldrini Research Center, Campinas, SP, Brazil).

The responsibilities of the chairperson (with support of all members) shall be:

• To propose and facilitate collaborative treatment protocols and projects on PACT;
• To oversee the progress of the collaborative projects undertaken by ICPACT;
• To seek funds on behalf of the ICPACT Workshops;
• To organize on-line regular meetings of the Plenum and at those meetings, to inform the Plenum of all significant ICPACT activities;
• To act on behalf of the Plenum in the periods between meetings of the Plenum.

Membership of the Plenum

Additional members and Institutions can also be appointed by any Founding Members. Membership in the Plenum carries with it acceptance of the following responsibilities:

• Attendance at regular meetings;
• Ethical use of information and biological material obtained through the ICPACT;
• Acceptance to submit scientific data relating to current studies of the ICPACT
• Adherence to the proprietary rules established by the Plenum regarding biological samples and clinical information, results of clinical or laboratory studies, and authorship;
• Adherence to the Good Clinical Practice (GCP) and national laws relating to the conduct and reporting of results of clinical trials.

The next coordinator will have the support of seven chairpersons:

1. Laboratory and Diagnostic Guidelines
2. Repository of Biological Materials or Patient/Research Subject Data
3. Web Registration and Auditing
4. Clinical studies
5. Chemotherapy and mitotane
6. Immunotherapy
7. Screening and Surveillance

In order to provide the foundation for future research, participants shall utilize a standard method for collecting and storing materials and data. Blood/plasma samples, ACT samples, and data relating to specific patients or research subjects will be collected by local researchers, according to the protocols implemented and the informed consent gained from patients or subjects.

Authorship

• All publications, proposed within the ICPACT, shall carry under the title the following citation: “A report from the International Consortium of Pediatric Adrenocortical Tumors (ICPACT)”;
• All articles proposed within the ICPACT shall be submitted for publication if approved in advance by the Steering Committee;
• Authorship order shall be previously established and will be according to extent of responsibility and participation of each ICPACT Member.